PATHOGENETIC MECHANISMS OF THROMBOEMBOLIC COMPLICATIONS OF THE METABOLIC SYNDROME IN PREGNANCY
Abstract
About the Authors
A. V. KhromylevRussian Federation
A. D. Makatsariya
Russian Federation
References
1. Dedov. I.I., Andreeva E.N., Karpova E.A.Sindrom polikistoznyh jaichnikov jetiologija, patogenez, diagnostika i lechenie: prakticheskie rekomendacii dlja vrachej. M. 2009; 51 c.
2. Makacarija A.D., Bicadze V.O. i dr. Antifosfolipidnyj sindrom – immunnaja trombofilija v akusherstve i ginekologii. M. 2013; 485 s.
3. Makacarija A.D., Beloborodova E.V., Bajmuradova S.M., Bicadze V.O. Gipergomocisteinemija i oslozhnenija beremennosti. M. 2007.
4. Makacarija A.D., Pshenichnikova E.B., Pshenichnikova T.B., Bicadze V.O. Metabolicheskij sindrom i trombofilija v akusherstve i ginekologii. M. 2006; 480 s. Alessi M.C., Juhan-Vague I. Metabolic syndrome, haemostasis and thrombosis. Thrombosis and Haemostasis. 2008; 99: 995-1000.
5. Alessi M.C., Juhan-Vague I. Metabolic syndrome, haemostasis and thrombosis. Thrombosis and Haemostasis. 2008; 99: 995-1000.
6. Andra H. James. Pregnancy-associated thrombosis. Hematology 2009; 277-285.
7. Anfossi G., Russo I., Trovati M. Platelet dysfunction in central obesity. Nutrition, Metabolism, and Cardiovascular Diseases. 2009; 19: 440-419.
8. Bates S.M., Greer I.A., Pabinger I. et al. Venous thromboembolism, thrombophilia, antithrombotic therapy, and pregnancy: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). Chest. 2008; 133: 844-886.
9. Bonetti P.O., Lerman L.O., Lerman A. Endothelial dysfunction: a marker of atherosclerotic risk. Arteriosclerosis, Thrombosis, and Vascular Biology. 2003; 23: 168-175.
10. Branch D.W., Khamashta M.A. Antiphospholipid syndrome: obstetric diagnosis, management, and controversies. Obstet. Gynecol. 2003; 101: 1333-1344.
11. Cornier M.A., Dabelea D., Hernandez T.L., Lindstrom R.C., Steig A.J., Stob N.R., Van Pelt R.E., Wang H., Eckel R.H. The metabolic syndrome. Endocrine Reviews. 2008; 29: 777-822.
12. Despre´s J.P., Lemieux I., Bergeron J., Pibarot P., Mathieu P., Larose E., Rode´s-Cabau J., Bertrand O.F., Poirier P. Abdominal besity and the metabolic syndrome: contribution to global cardiometabolic risk. Arteriosclerosis, Thrombosis, and Vascular Biology. 2008; 28: 1039-1049.
13. Diamant M., Nieuwland R., Pablo R.F., Sturk A., Smit J.W., Radder J.K. Elevated numbers of tissue-factor exposing microparticles correlate with components of the metabolic syndrome in uncomplicated type 2 diabetes mellitus. Circulation. 2002; 106: 2442-2447.
14. Fay W.P., Garg N. Sunkar M. Vascular functions of the plasminogen activation system. Arteriosclerosis, Thrombosis, and Vascular Biology. 2007; 27: 1231-1237.
15. Franchini M., Targher G., Montagnana M. Lippi G. Themetabolic syndrome and the risk of arterial and venousthrombosis. Thrombosis Research. 2008; 122: 727-735.
16. Horvath B., Bodecs T., Boncz I., Bodis J. Metabolic syndrome in normal and complicated pregnancies. Metab. Syndr. Relat. Disord. 2013 Jun; 11 (3): 185-8.
17. Jacobsen A.F., Skjeldestad F.E., Sandset P.M. Incidence and risk patterns of venous thromboembolism in pregnancy and puerperium – a register-based casecontrol study. Am. J. Obstet. Gynecol. 2008; 198: 233 e231-237.
18. James A.H. Venous thromboembolism in pregnancy. Arterioscler. Thromb. Vasc. Biol. 2009; 29: 326-331.
19. Jara L.J., Medina G., Vera-Lastra O. Systemic antiphospholipid syndrome and atherosclerosis. Clin. Rev. Allergy Immunol. 2007 Apr; 32 (2): 172-7.
20. Kim J.A., Montagnani M., Koh K.K., Quon M.J. Reciprocal relationships between insulin resistance and endothelial dysfunction: molecular and pathophysiological mechanisms. Circulation. 2006; 113: 1888- 1904.
21. Kobashi G., Ohta K., Yamada H., Hata A., Minakami H., Sakuragi N., Tamashiro H., Fujimoto S. Hokkaido. 4G/5G variant of plasminogen activator inhibitor-1 gene and severe pregnancy-induced hypertension: subgroup analyses of variants of angiotensinogen and endothelial nitric oxide synthase. J. Epidemiol. 2009; 19 (6): 275-80.
22. Kotronen A., Yki-Järvinen H. Fatty liver: a novel component of the metabolic syndrome. Arteriosclerosis, Thrombosis, and Vascular Biology. 2008; 28: 27-38.
23. Leila M., Ariane R., Maria S., Claudia B. Metabolic syndrome components in arterial hypertension. Rev. Esc. Enferm. USP. 2012; 46 (6): 1349-54.
24. Li H., Forstermann U. Nitric oxide in the pathogenesis of vascular disease. Journal of Pathology. 2000; 190: 244-254.
25. Mina A., Favaloro E.J., Koutts J. Hemostatic dysfunction associated with endocrine disorders as a major risk factor and cause of human morbidity and mortality: a comprehensive meta-review. Seminars in Thrombosis and Hemostasis. 2007; 33: 798-809.
26. Neville C., Rauch J., Kassis J., Chang E.R., Joseph L., Le Comte M., Fortin P.R. Thromboembolic risk in patients with high titre anticardiolipin and multiple antiphospholipid antibodies. Thromb. Haemost. 2003 Jul; 90 (1): 108-15.
27. Nieuwdorp M., Stroes E.S., Meijers J.C., Bu¨ller H. Hypercoagulability in the metabolic syndrome. Current Opinion in harmacology. 2005; 5: 155-159.
28. Olufadi R., Byrne C.D. Effects of VLDL and remnant particles on platelets. Pathophysiology of Haemostasis and Thrombosis. 2006; 35: 281-291.
29. Randriamboavonjy V., Fleming I. Insulin, insulin resistance, and platelet signaling in diabetes. Diabetes Care. 2009; 32: 528-530.
30. Robertson L. Wu O., Langhorne P. et al. Thrombophilia in pregnancy: a systematic review. Br. J. Haematol. 2006; 132: 171-196.
31. Shamshirsaz A.A., Paidas M., Krikun G. Preeclampsia, hypoxia, thrombosis, and inflammation. J. Pregnancy. 2012; 2012: 374047.
32. Shoelson S.E., Lee J., Goldfine A.B. Inflammation and insulin resistance. Journal of Clinical Investigation. 2006; 116: 1793-1801.
33. Targher G., Chonchol M., Miele L., Zoppini G., Pichiri I. Muggeo M. Nonalcoholic fatty liver disease as a contributor to hypercoagulation and thrombophilia in the metabolic syndrome. Seminars in Thrombosis and Hemostasis. 2009; 35: 277-287.
34. Targher G., Bertolini L., Rodella S., Lippi G., Franchini M., Zoppini G., Muggeo M., Day C.P. NASH predicts plasma inflammatory biomarkers independently of visceral fat in men. Obesity. 2008; 16: 1394-1399.
35. Targher G. Non-alcoholic fatty liver disease, cardiovasthe metabolic syndrome and the risk of cardiovascular disease: the plot thickens. Diabetic Medicine. 2007; 24: 1-6.
36. Van Gaal L.F., Mertens I.L., De Block C.E. Mechanisms linking obesity with cardiovascular disease. Nature. 2006; 444: 875-880.
37. Viall CA, Chen Q, Liu B, Hickey A, Snowise S, Salmon JE, Stone PR, Chamley L.W. Antiphospholipid antibodies internalised by human syncytiotrophoblast cause aberrant cell death and the release of necrotic trophoblast debris. J. Autoimmun. 2013 Sep 12; pii: S0896-8411(13)00111-X. doi: 10.1016/j. jaut.2013.08.005. [Epub ahead of print].
38. Weisberg S.P., McCann D., Desai M., Rosenbaum M., Leibel R.L., Ferrante A.W. Obesity is associated with macrophage ccumulation in adipose tissue. Journal of Clinical Investigation. 2003; 112: 1796-1808.
39. Xie H., Sheng L., Zhou H., Yan J. The role of TLR4 in pathophysiology of antiphospholipid syndrome-associated thrombosis and pregnancy morbidity. Br J. Haematol. 2013 Oct 8; doi: 10.1111/bjh.12587. [Epub ahead of print].
40. Zhang D., Jiang X., Fang P., Yan Y., Song J., Gupta S., Schafer A.I., Durante W., Kruger W.D., Yang X., Wang H. Hyperhomocysteinemia promotes inflammatory monocyte generation and accelerates atherosclerosis in transgenic cystathionine beta-synthase-deficient mice. Circulation. 2009 Nov 10; 120 (19): 1893-902.
41.
42.
Review
For citations:
Khromylev A.V., Makatsariya A.D. PATHOGENETIC MECHANISMS OF THROMBOEMBOLIC COMPLICATIONS OF THE METABOLIC SYNDROME IN PREGNANCY. Obstetrics, Gynecology and Reproduction. 2014;8(1):68-73. (In Russ.)
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.